Manipulating selectivity through gatekeeper interactions: Inhibition of EGFR and its T790M mutant

被引：0

作者：

Hanan, Emily ^{[1
]}

Bryan, Marian ^{[1
]}

Burdick, Daniel ^{[1
]}

Chan, Bryan ^{[1
]}

Chen, Yuan ^{[1
]}

Eigenbrot, Charles ^{[1
]}

Heald, Robert ^{[2
]}

Heffron, Timothy ^{[1
]}

La, Hank ^{[1
]}

Purkey, Hans ^{[1
]}

Schaefer, Gabriele ^{[1
]}

Schmidt, Stephen ^{[1
]}

Seward, Eileen ^{[2
]}

Sideris, Steve ^{[1
]}

Wang, Shumei ^{[1
]}

Yu, Christine ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

[2] Discovery Charles River, Harlow, Essex, England

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

620

引用

页数：1

共 50 条

[31] HIGH PREVALENCE OF GERMLINE EGFR T790M MUTATIONS IN LUNG CANCER PATIENTS WHOSE TUMORS HARBOR BASELINE T790M
Oxnard, Geoffrey R.
Arcila, Maria E.
Kris, Mark G.
Ladanyi, Marc
Miller, Vincent A.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S510 - S511
[32] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Skoulidis, Ferdinandos
Papadimitrakopoulou, Vassiliki A.
CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
[33] Discovery of a potent dual ALK and EGFR T790M inhibitor
Jang, Jaebong
Son, Jung Beom
To, Ciric
Bahcall, Magda
Kim, So Young
Kang, Seock Yong
Mushajiang, Mierzhati
Lee, Younho
Janne, Pasi A.
Choi, Hwan Geun
Gray, Nathanael S.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 136 : 497 - 510
[34] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
Ma, W.
Gong, J.
Shan, J.
Lewis, D.
Xiao, W.
Hung, J.
Moore, E. H.
Zhang, Y.
Mans, N. Z.
Welborn, J.
Lam, K. S.
Li, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1863 - S1864
[35] GefitinibDevelopment of resistant EGFR T790M mutation: case report
Reactions Weekly, 2016, 1593 (1) : 91 - 91
[36] Investigating the Selectivity of Allosteric Inhibitors for Mutant T790M EGFR over Wild Type Using Molecular Dynamics and Binding Free Energy Calculations
Tinivella, Annachiara
Rastelli, Giulio
ACS OMEGA, 2018, 3 (12): : 16556 - 16562
[37] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
Tseng, Jeng-Sen
Su, Kang-Yi
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Chen, Hsuan-Yu
Tsai, Chi-Ren
Yu, Sung-Liang
Chang, Gee-Chen
ONCOTARGET, 2016, 7 (30) : 48059 - 48069
[38] Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia
Cai-Hong Yun
Eunyoung Park
Dalia Ercan
Mari Manuia
Jose Juarez
Chunxiao Xu
Kevin Rhee
Ting Chen
Haikuo Zhang
Sangeetha Palakurthi
Jaebong Jang
Gerald Lelais
Michael DiDonato
Badry Bursulaya
Pierre-Yves Michellys
Robert Epple
Thomas H. Marsilje
Matthew McNeill
Wenshuo Lu
Jennifer Harris
Steven Bender
Kwok-Kin Wong
Pasi A. Jänne
Michael J. Eck
Nature, 2016, 534 : 129 - 132
[39] EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Yamada, Teppei
Azuma, Koichi
Muta, Emi
Kim, Jintaek
Sugawara, Shunichi
Zhang, Guang Lan
Matsueda, Satoko
Kasama-Kawaguchi, Yuri
Yamashita, Yuichi
Yamashita, Takuto
Nishio, Kazuto
Itoh, Kyogo
Hoshino, Tomoaki
Sasada, Tetsuro
PLOS ONE, 2013, 8 (11):
[40] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, Sha
Li, Xuefei
Zhao, Chao
Jiang, Tao
Jia, Yijun
Shi, Jinpeng
He, Yayi
Li, Jiayu
Zhou, Fei
Gao, Guanghui
Li, Wei
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2019, 128 : 33 - 39

← 1 2 3 4 5 →